Terms: = Ovarian cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA
515 results:
1. Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast cancer-Associated Germline Pathogenic Variants in Mexico.
Mesa-Chavez F; Chavarri-Guerra Y; Aguilar-Y-Mendez D; Becerril-Gaitan A; Vaca-Cartagena BF; Carrillo-Bedoya A; Santiesteban-González S; Aranda-Gutierrez A; Rodríguez-Faure A; Obregon-Leal D; Quintero-Beuló G; Rodriguez-Olivares JL; Miaja M; Weitzel JN; Villarreal-Garza C
JCO Glob Oncol; 2024 Apr; 10():e2300417. PubMed ID: 38635940
[TBL] [Abstract] [Full Text] [Related]
2. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant ovarian cancer: Final Overall Survival and Biomarker Analyses.
Konstantinopoulos PA; Cheng SC; Lee EK; da Costa AABA; Gulhan D; Wahner Hendrickson AE; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Penson RT; Stover EH; Curtis J; Sawyer H; Polak M; Chowdhury D; D'Andrea AD; Färkkilä A; Shapiro GI; Matulonis UA
JCO Precis Oncol; 2024 Apr; 8():e2300635. PubMed ID: 38635934
[TBL] [Abstract] [Full Text] [Related]
3. Therapeutic Options Targeting the ataxia-Telangiectasia Mutated (atm)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in ovarian cancer.
Tseng CC; Ku MH; Wu YC; Huang WL; Wu WM; Pai CH; Chen CW
Anticancer Res; 2024 Apr; 44(4):1353-1364. PubMed ID: 38538001
[TBL] [Abstract] [Full Text] [Related]
4. Upgrade Rates and Breast cancer Development Among Germline Pathogenic Variant Carriers with High-Risk Breast Lesions.
Laws A; Leonard S; Hershey E; Stokes S; Vincuilla J; Sharma E; Milliron K; Garber JE; Merajver SD; King TA; Pilewskie ML
Ann Surg Oncol; 2024 May; 31(5):3120-3127. PubMed ID: 38261128
[TBL] [Abstract] [Full Text] [Related]
5. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and ovarian cancer (HBOC) by next-generation sequencing.
Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
Kim JH; Kim SI; Park EY; Kim ET; Kim H; Kim S; Park SY; Lim MC
Gynecol Oncol; 2024 Feb; 181():33-39. PubMed ID: 38104527
[TBL] [Abstract] [Full Text] [Related]
7. PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/ovarian cancer.
Ghosh M; Kang MS; Katuwal NB; Hong SD; Jeong YG; Park SM; Kim SG; Moon YW
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069409
[TBL] [Abstract] [Full Text] [Related]
8. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract] [Full Text] [Related]
9. Rate of Pathogenic Germline Variants in Patients With Lung cancer.
Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
[TBL] [Abstract] [Full Text] [Related]
10. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in cancer Cells and Improve Response to PARP Inhibition and Chemotherapies.
Carter J; Hulse M; Sivakumar M; Burtell J; Thodima V; Wang M; Agarwal A; Vykuntam K; Spruance J; Bhagwat N; Rager J; Ruggeri B; Scherle P; Ito K
Cancer Res Commun; 2023 Nov; 3(11):2233-2243. PubMed ID: 37861290
[TBL] [Abstract] [Full Text] [Related]
11. Ethnicity-specific BRCA1, BRCA2, PALB2, and atm pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.
Sokolenko AP; Bakaeva EK; Venina AR; Kuligina ES; Romanko AA; Aleksakhina SN; Belysheva YV; Belogubova EV; Stepanov IA; Zaitseva OA; Yatsuk OS; Togo AV; Khamgokov ZM; Kadyrova AO; Pirmagomedov AS; Bolieva MB; Epkhiev AA; Tsutsaev AK; Chakhieva MD; Khabrieva KM; Khabriev IM; Murachuev MA; Buttaeva BN; Baboshkina LS; Bayramkulova FI; Katchiev IR; Alieva LK; Raskin GA; Orlov SV; Khachmamuk ZK; Levonyan KR; Gichko DM; Kirtbaya DV; Degtyariov AM; Sultanova LV; Musayeva HS; Belyaev AM; Imyanitov EN
Breast Cancer Res Treat; 2024 Jan; 203(2):307-315. PubMed ID: 37851290
[TBL] [Abstract] [Full Text] [Related]
12. Hepatitis B virus infection disrupts homologous recombination in hepatocellular carcinoma by stabilizing resection inhibitor ADRM1.
Zeng M; Tang Z; Ren L; Wang H; Wang X; Zhu W; Mao X; Li Z; Mo X; Chen J; Han J; Kong D; Ji J; Carr AM; Liu C
J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 37815873
[TBL] [Abstract] [Full Text] [Related]
13. Mosaic
Schwartz M; Ibadioune S; Chansavang A; Vacher S; Caputo SM; Delhomelle H; Wong J; Abidallah K; Moncoutier V; Becette V; Popova T; Suybeng V; De Pauw A; Stern MH; Colas C; Mouret-Fourme E; Stoppa-Lyonnet D; Golmard L; Bieche I; Masliah-Planchon J
J Med Genet; 2024 Feb; 61(3):284-288. PubMed ID: 37748860
[TBL] [Abstract] [Full Text] [Related]
14. ovarian squamous cell carcinoma associated with teratoma: a report of six cases with genomic analysis.
Liang Y; Ruan H; Yu M; Lü B
Pathology; 2023 Dec; 55(7):966-973. PubMed ID: 37739924
[TBL] [Abstract] [Full Text] [Related]
15. Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC).
Fernández Madrigal L; Rodríguez Garcés MY; Jiménez Ruiz FJ
Curr Probl Cancer; 2023 Dec; 47(6):101008. PubMed ID: 37704491
[TBL] [Abstract] [Full Text] [Related]
16. ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
[TBL] [Abstract] [Full Text] [Related]
17. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
[TBL] [Abstract] [Full Text] [Related]
18. Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.
Mandelker D; Marra A; Zheng-Lin B; Selenica P; Blanco-Heredia J; Zhu Y; Gazzo A; Wong D; Yelskaya Z; Rai V; Somar J; Ostafi S; Mehta N; Yang C; Li Y; Brown DN; da Silva EM; Pei X; Linkov I; Terraf P; Misyura M; Ceyhan-Birsoy O; Ladanyi M; Berger M; Pareja F; Stadler Z; Offit K; Riaz N; Park W; Chou J; Capanu M; Koehler M; Rosen E; O'Reilly EM; Reis-Filho JS
J Clin Oncol; 2023 Nov; 41(33):5151-5162. PubMed ID: 37607324
[TBL] [Abstract] [Full Text] [Related]
19. Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.
Wilcox N; Dumont M; González-Neira A; Carvalho S; Joly Beauparlant C; Crotti M; Luccarini C; Soucy P; Dubois S; Nuñez-Torres R; Pita G; Gardner EJ; Dennis J; Alonso MR; Álvarez N; Baynes C; Collin-Deschesnes AC; Desjardins S; Becher H; Behrens S; Bolla MK; Castelao JE; Chang-Claude J; Cornelissen S; Dörk T; Engel C; Gago-Dominguez M; Guénel P; Hadjisavvas A; Hahnen E; Hartman M; Herráez B; ; Jung A; Keeman R; Kiechle M; Li J; Loizidou MA; Lush M; Michailidou K; Panayiotidis MI; Sim X; Teo SH; Tyrer JP; van der Kolk LE; Wahlström C; Wang Q; Perry JRB; Benitez J; Schmidt MK; Schmutzler RK; Pharoah PDP; Droit A; Dunning AM; Kvist A; Devilee P; Easton DF; Simard J
Nat Genet; 2023 Sep; 55(9):1435-1439. PubMed ID: 37592023
[TBL] [Abstract] [Full Text] [Related]
20. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract] [Full Text] [Related]
[Next]
